FY 2015 ADUFA Performance Report
Acting Commissioner’s Report
On This reauthorization of ADUFA for another 5-year period (FY 2014 through FY 2018) is referred to as ADUFA III. This report marks the second year of ADUFA III.
This report details FDA’s preliminary performance for FY 2015, and finalizes performance results for FY 2014. It is my pleasure to report that FDA exceeded almost all performance goals for FY 2014. The Agency also met review-time goals for all FY 2015 cohort submissions reviewed or due for review by September 30, 2015. With reviews pending, FDA has the potential to exceed all performance goals for FY 2015.
We are dedicated to exploring new approaches and technologies that offer high-quality, cost-effective improvements in the Agency’s review of new animal drug applications and submissions. Under the leadership of the President and in collaboration with Congress and industry, FDA looks forward to the continued success and significant improvements in the animal drug review process made achievable by ADUFA.
Stephen M. Ostroff, M.D.
Acting Commissioner of Food and Drugs